TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06744803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified Neuropathy Management Application on Cancer Behavior
Description: The study will be conducted in three phases:~Phase 1: The content of the gamified neuropathy management application used in the study will be prepared by the researchers using relevant literature.~Phase 2: The developed gamified neuropathy management application will be introduced to patients during one-on-one interviews at the daytime chemotherapy clinic. After collecting pre-test data, the application will be sent to the patients, who will be asked to use it for 8 weeks.~Phase 3: Following the start of the study's implementation, patients will be contacted in the 4th and 8th weeks to collect mid-study and post-test data.
Study: NCT06108323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theapeutic exercise plus action observation training
Description: Participants make an observation of actions related to the training they are going to perform. Subsequently, they perform the therapeutic exercise session.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise plus sham observation training
Description: Participants make a sham observation. Subsequently, they perform the therapeutic exercise session.
Study: NCT05485727

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physical Therapy
Description: Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
Study: NCT04713917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronique Acid Gel
Description: Vaginal gel based on HA with liposomal structure applicated 2 times a week
Study: NCT06744543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIGHT Prompted Provider Message
Description: Among patients surpassing a 0.30 probability threshold that have a scheduled visit to pediatric primary care at VUMC, 500 will be randomized to the intervention and a SIGHT-prompted provider message will be generated.
Study: NCT06743789

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 1 (3 participants) - will receive a dose of 20 Gy (Gray, a measurement of radiation) in a single study intervention (one study intervention day)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 2 (3 participants) - will receive a dose of 15 Gy in a single study intervention (one study intervention day)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 3 (3 participants) - will receive a dose of 10 Gy in a single study intervention (one study intervention day)
Study: NCT04713917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser CO2
Description: The laser energy delivered along the vaginal wall heats the tissue without damaging it.
Study: NCT05419505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered by subcutaneous injection.
Study: NCT04713917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronique Acid Injection
Description: HA injection performed under the mucosae (2-3mm in depth) following one injection point every 5mm on the 3 first cm of the vagina and on the posterior part of the introitus.
Study: NCT06743789

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 1 (3 participants) - will receive a dose of 12 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 36Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 2 (3 participants) - will receive a dose of 10 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 30Gy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Group 3 (3 participants) - will receive a dose of 8 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 24Gy)
Study: NCT06745817

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessement of nutritional status
Description: Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)

Intervention type: DIAGNOSTIC_TEST
Intervention: Dermis density and thickness
Description: Dermis density and thickness will be measured using ultrasonography with Cortex DermaLab 20 MHz US probe.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin elasticity
Description: Skin elasticity will be measured using Cortex DermaLab elasticity probe.

Intervention type: DIAGNOSTIC_TEST
Intervention: Body composition measurement
Description: Body composition will be measured using Biostat Multiscan 5000.

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening questionnaire
Description: Screening questionnaire: assessment of socio-demographic parameters, use of food supplements, health status, dietary habits

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening questionnaire
Description: Screening questionnaire: assessment of socio-demographic parameters, use of food supplements, health status, dietary habits
Study: NCT06745167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed field ablation
Description: Utilizing pulsed field ablation (PFA), combining pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation alone
Description: Using conventional radiofrequency ablation technology, combines pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation
Study: NCT06745206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized Recombinant Human Brain Natriuretic Peptide
Description: Prior to rh-BNP administration, measure: PiCCO indices, hemodynamic parameters, venous return, tissue perfusion, echocardiographic parameters, ultrasound indices, 2-hour averaged urine output and fluid balance. Repeat all above-mentioned measurements at 30 minutes post-initiation.
Study: NCT06744686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-102
Description: 50mg, 150mg, 300mg, 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-102
Description: 50mg, 150mg, 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06743568

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcatheter aortic valve replacement
Description: Eligible patients will be randomized 1:1 to self-expandable valve group or balloon-expandable valve group.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcatheter aortic valve replacement
Description: Eligible patients will be randomized 1:1 to self-expandable valve group or balloon-expandable valve group.
Study: NCT06743555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation without surgery
Description: Patients randomized to this arm will forego standard-of-care thoracic surgery and will undergo strict surveillance based on serial radiological follow-up and ctDNA monitoring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care surgery
Description: Patients randomized to this arm will undergo standard-of-care thoracic surgery and undergo post-operative surveillance with serial radiological follow-up and ctDNA monitoring
Study: NCT06744010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub sartorial canal block and popliteal block in ankle surgeries
Description: All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral block and popliteal block in ankle surgeries
Description: * All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4.
Study: NCT06735950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteering in Place Program
Description: Implementation of the VIP Program consists of 4 steps guided by the Social Ecological Model (SEM) with Interpersonal interventions guided by Social Cognitive Theory (SCT), and will be implemented over a 6-month period by research supported Volunteer Coordinators. The four steps of the VIP Program are: Step 1: Stakeholder Team, Staff and Family Education; Step 2: Assessment of AL Environment and Residents Abilities and Interests; Step 3: Ongoing Implementation of the Volunteer Plan; and Step 4: Reassessment of the Volunteer Activity. Participants will volunteer three time per week for approximately 30 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recreational activity
Description: The Recreational Activities group intervention will consist of similar staff education regarding the benefits of engaging residents in meaningful activities as described in Step 1 above, without other steps associated with the VIP Program. The Recreational Activities group will be exposed to a research team RA coordinator who will provide a current events activity (reviewing the daily newspaper) for the participants in the RA group three times per week for approximately 30 minutes as an attention control.
Study: NCT06745466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganirelix acetate
Description: Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration. Women will self-administer subcutaneous injections (0.25 mg/day in 0.5 ml of normal saline) of the GnRH antagonist ganirelix acetate (Antagon, Organon, Inc., West Orange, New Jersey,) every day for \~12-15 days (starting on day \~2-4 of the menstrual cycle). Testing will occur on day 3-4 and day14-15 of using Antagon.
Study: NCT06744712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Testing
Description: Pharmacogenomic testing will be completed by the vendor. The vendor is certified under CLIA-88 and accredited by the College of American Pathologists as qualified to perform high-complexity testing. Genomic DNA extracted from the swab will be analyzed by PCR using Thermo Fisher TaqMan® and/or LGC Biosearch BHQ® probe-based methods to interrogate the variant locations listed in (See Appendix II). Twenty-seven genes are evaluated and reported.
Study: NCT06745947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT
Description: Participants who meet the eligibility criteria will receive the EFT intervention, a cognitive training exercise designed to help them generate and visualize future events or goals. The intervention will be administered individually, in person, by a trained counselor
Study: NCT06745245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional counseling and supplementation with a gelatin with prebiotic fiber and probiotic microorganisms
Description: One serving (15 g) of symbiotic gelatin
Study: NCT06744517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sprint Interval Training
Description: 6 sessions of sprint interval training over 2 weeks. Each session involves 4-6 x 30 second Wingate sprints with 4 minutes of recovery in between on a stationary bike

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training
Description: 6 sessions of sprint interval training over 2 weeks. Each session involves 4-6 x 30 second Wingate sprints with 4 minutes of recovery in between on a stationary bike
Study: NCT04567615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study: NCT04764357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Scalp Cooling System
Description: Scalp cooling will begin at least 30-45 minutes prior to administration of each chemotherapy (45 minutes for those with thick or coarse hair types). Scalp temperature will be maintained at +3°C (37°F) throughout drug administration and for at least 120-180 minutes after discontinuing the infusion. Scalp cooling will occur with each dose of chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alopecia Assessments
Description: Photographs will be taken prior to the use of the scalp cooling system and once at the end of the study. Patients with solid tumors will have additional photographs taken after every 2 cycles of chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes Questionnaires
Description: * Selected questions from NCI PRO-CTCAE™, Chemotherapy-Induced Alopecia Distress Scale (CADS), and PediQUEST Memorial Symptom Assessment Scale, at the following time points: baseline, after every 2 cycles of chemotherapy, 4 week follow up and end of study.~* Tolerability Questionnaire each time the cooling cap is used and at the end of study
Study: NCT04921306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol Hydrochloride
Description: Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.
Study: NCT05856942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health service - home-based PrEP monitoring
Description: Home-based PrEP care
Study: NCT05269797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led health coaching re: heart failure self-care management
Description: A focus group meeting will be arranged with the nurse participants to provide training on the study intervention specific to the Nurse-led health coaching intervention. The intervention involves identifying barriers and finding strategies and solutions to self-care management, while employing a self-care HF management tool of adjusting diuretic dosing (ADD) according to the congestive cardiac calendar (designed in collaboration with nurses in Phase 1). It will be essential for the nurses to document key information pertaining to the rationale for these decision-making strategies or solutions. This is in comparison to the standard of care in primary health care of nurses not taking a standardize approach towards health coaching and the patient being instructed by the practitioner to take a set diuretic dosing (SDD).
Study: NCT05645887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution from day 0 to day 7.
Study: NCT04985682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.
Study: NCT06255626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD40.RBDv vaccin (SARS-Cov2 Vaccin)
Description: 1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD40.RBDv vaccin (SARS-Cov2 Vaccin)
Description: 1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD40.RBDv vaccin (SARS-Cov2 Vaccin)
Description: 1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD40.RBDv vaccin (SARS-Cov2 Vaccin)
Description: 1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))
Study: NCT05668403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B007
Description: Drug: B007 injection Drug: Placebo injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B007
Description: Drug: B007 injection Drug: Placebo injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B007
Description: Drug: B007 injection Drug: Placebo injection
Study: NCT05440214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Training
Description: Dialectical Behavior Therapy Skills Training (DBT-ST) is a group-based intervention focused on teaching skills for improving emotion regulation. The sessions will be offered in-person or via approved telehealth services.
Study: NCT06166602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG block with 0.25% bupivacaine.
Description: Peng block will be applied to the same side as the surgery, using 0.25% bupivacaine at the same concentration in different volumes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG block with 0.25% bupivacaine.
Description: Peng block will be applied to the same side as the surgery, using 0.25% bupivacaine at the same concentration in different volumes.
Study: NCT06275607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Affective Therapy
Description: Active training in regulating anger.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Emotional Discussion
Description: General discussion of emotions; no therapy or training is offered.
Study: NCT04761393

Intervention type: PROCEDURE
Intervention: Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI
Description: Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds
Study: NCT06465186

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: Efinopegdutide is given as a subcutaneous injection using a single-use prefilled syringe, once per week for 28 weeks

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given as a subcutaneous injection using a single-use prefilled syringe once per week for 28 weeks.
Study: NCT06351904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAG-01
Description: RAG-01 is a therapeutic small activating RNA (saRNA).
Study: NCT06220474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Thermage FLX System
Description: The Thermage FLX System is tested for its therapeutic efficacy and safety on treating refractory Meibomian Gland Dysfunction

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment acts as a control to test the therapeutic efficacy and safety of The Thermage FLX System
Study: NCT05000190

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active capsule
Description: 1 capsule daily for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 1 capsule daily for 28 days
Study: NCT04968782

Intervention type: OTHER
Intervention: Patients with acute appendicitis
Description: No intervention, single survey
Study: NCT05846087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep retraining therapy
Description: Sleep retraining therapy improves sleep efficiency (total sleep time/total time in bed) by reducing the amount of time spent in bed awake. The digitally designed version which SleepFix delivers uses an algorithm which requires the users current sleep times and ideal wake-up time to determine when one should get into bed to fall asleep and when one should get out of bed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleep health education modules
Description: educational modules about sleep and insomnia; its causes; and its impact on various aspects of life. This information is arranged into three modules which will be provided to participants over three weeks.